Hepatic T-cell dysfunction in chronic liver disease and hepatocellular carcinoma: a spatial systems immunology framework for precision immunotherapy

Expert Opinion on Therapeutic Targets · Published 2026-07-30 · DOI 10.1080/14728222.2026.2708824

Authors (1)

Wanvisa Udomsinprasert

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Udomsinprasert, W. (2026). Hepatic T-cell dysfunction in chronic liver disease and hepatocellular carcinoma: a spatial systems immunology framework for precision immunotherapy. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2026.2708824

Related articles

• Oxidative stress and cellular senescence: Roles in tumor progression and therapeutic opportunities · MedComm – Oncology · 2024 · Cites or is cited by this article
• Advancements in the molecular understanding of major depressive disorder uncovering novel targets with therapeutic promise: focus on recurrence of illness · Expert Opinion on Therapeutic Targets · 2025 · Same journal
• Modulating tonic NMDA receptor currents: mechanistic insights into ketamine, esketamine, and dextromethorphan for major depressive disorder and implications for the discovery and development of investigational agents · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• Molecular targets in gastric cancer for nanomedicine therapeutics: mechanistic insights and translational progress · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• AQP7 suppresses cell stemness and metastasis by targeting Wnt signaling in basal-like breast cancer · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• CDK7 as a New therapeutic target in pancreatic and lung cancer: current evidence and future perspectives · Expert Opinion on Therapeutic Targets · 2025 · Same journal
• Advances in CGRP therapeutic targets for migraine: where do we stand 5 years later? · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• Transient receptor potential (TRP) channels: an emerging therapeutic target for the treatment of cardiac hypertrophy · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• Lipopolysaccharide-targeting treatments for multidrug-resistant Pseudomonas aeruginosa · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• 5-FU in combination with PARP inhibitor ABT-888 deregulates MGMT-dependent mismatch repair (MMR) pathway in MMR-proficient colorectal cancer stem cells by modulating MGMT/PARP1/MSH6 complex · Expert Opinion on Therapeutic Targets · 2026 · Same journal